Arteriosclerosis and arteriosclerosis-related disease marker

An arteriosclerosis and marker technology, applied in disease diagnosis, cardiovascular system diseases, anti-animal/human immunoglobulin, etc., can solve problems such as unsuitability and unacceptable inspection throughput, and achieve the effect of avoiding deterioration.

Pending Publication Date: 2021-11-12
EIKEN KAGAKU +1
View PDF0 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

These examinations can be performed in many hospitals because they require less than ten minutes and are non-invasive and easy to investigate the progress of arteriosclerosis. Compared with blood tests, etc., it is obviously not suitable for screening large-scale population groups with high risk of arteriosclerosis in terms of throughput for screening tests

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Arteriosclerosis and arteriosclerosis-related disease marker
  • Arteriosclerosis and arteriosclerosis-related disease marker
  • Arteriosclerosis and arteriosclerosis-related disease marker

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0110] The relationship between serum NPC2 value and maxIMT value, plaque

[0111] Patients with aortic aneurysm, aortic dissection, arteriosclerotic occlusive disease of the lower extremities, and myocardial infarction were used as subjects, and the serum concentration of NPC2 was measured by ELISA, the maxIMT value of the carotid bulb by ultrasound examination, and the carotid artery Comparison of ultrasonographic plaque findings (with and without plaque). NPC2 was determined by using NPC2 ELISA kit (AvivaSystems Biology Company) and following the protocol attached to the kit. The maxIMT value is the maximum wall thickness including carotid bulb plaque measured using the Aplio series manufactured by Canon Medical Systems Co., Ltd. In the ultrasonography, the group in which the presence of plaque was confirmed was defined as the plaque presence (plaque) group, and the group in which no obvious plaque was confirmed was defined as the plaque-free group, thereby determining the...

Embodiment 2

[0117] The relationship between serum NPC2 value and baPWV value

[0118] Patients with aortic aneurysm, aortic dissection, lower extremity arteriosclerotic obliterans and myocardial infarction were used as subjects, and the serum concentration of NPC2 was measured by ELISA method, and compared with the baPWV value. The serum concentration of NPC2 was measured according to the method described in Example 1. The baPWV value was measured using BP-203RPEII (Exceed) manufactured by Nippon Colin Corporation.

[0119] The comparative analysis of serum NPC2 value and baPWV value was carried out as follows: For a total of 85 cases (49 cases of aortic aneurysm, 11 cases of aortic dissection, 8 cases of lower extremity arteriosclerotic obliterans, and 17 cases of myocardial infarction), the critical value of baPWV was used as 1400 (cm / s) or 1700 (cm / s) were divided into two groups, and the serum NPC2 value of each group was investigated. Mann-Whitney's U test was used in statistical p...

Embodiment 3

[0122] The relationship between serum IGFBP7 value and maxIMT value, plaque

[0123] The same patient as in Example 1 was used as a test subject, and the serum concentration of IGFBP7 was measured by ELISA, and the maxIMT value of the carotid bulb and the plaque found by carotid ultrasound examination (with or without plaque) were carried out. )Comparison. IGFBP7 was measured using an ELISA kit for insulin-like growth factor binding protein 7 (cloud-clone company), and was measured according to the protocol attached to the kit. The measurement of the maxIMT value and the determination of the presence or absence of plaque were carried out according to the method described in Example 1.

[0124]Specifically, in the measurement of the IGFBP7 concentration by the ELISA method, a diluted serum sample was added to the solid phase plate of the anti-IGFBP7 antibody and incubated. Then, remove the sample solution, add detection reagent A solution and incubate. After the incubation, ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
Sensitivityaaaaaaaaaa
Login to view more

Abstract

The purpose of the present invention is to provide a novel biomarker for detecting an arteriosclerosis-related disease or for assessing the progress of arteriosclerosis. Specifically, the present invention pertains to a marker which includes Niemann-Pick disease type C2 (NPC2) protein and / or insulin-like growth factor-binding protein 7 (IGFBP7) protein, and which is for detecting an arteriosclerosis-related disease or for assessing the progress of arteriosclerosis.

Description

technical field [0001] The invention relates to the technical field of a clinical inspection agent for assisting the diagnosis of arteriosclerosis-related diseases and arteriosclerosis. In detail, it relates to biomarkers of arteriosclerosis-related diseases, biomarkers reflecting the state of arteriosclerosis (hereinafter also referred to as "degree of progress"), measurement reagents and kits using these biomarkers, and detection of arteriosclerosis-related diseases Methods and methods for evaluating the degree of progression of arteriosclerosis. Background technique [0002] Arteriosclerosis is a general term for the state in which various substances are deposited inside the artery, causing the inner wall of the artery to thicken, harden, lose elasticity, and narrow the lumen. Although it is divided into three types: atherosclerosis (hereinafter referred to as atherosclerosis), medial calcification, and arteriosclerosis, arteriosclerosis generally refers to atheroscleros...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): G01N33/53C07K16/18C07K16/24G01N33/68
CPCC07K16/18A61P9/10G01N2800/323G01N33/6893G01N2333/4745G01N2333/4737G01N33/54306
Inventor 南野直人八木宽阳锦织充広植田初江松田均村上裕辅
Owner EIKEN KAGAKU
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap